Request Offering Information

Click here to load this Caspio Cloud Database


Thank you for visiting the PetLife Pharmaceuticals, Inc. Investor Relations and Information page. We are currently updating our website and will provide a secure access section for investors and the public sections for information and data. Any questions, please CLICK HERE

1 844 4 PETLIFE
(844) 473-8543
info@petlifelifepharma.com



PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

LEGAL COUNSEL
Lance Brunson, Esq., of Brunson Chandler & Jones PLLC (“BCJ”)
175 S. Main Street, Suite 1410, Salt Lake City, Utah 84111

Independent Accountant
LBB & Associates Ltd., LLP
10260 Westheimer Road, Suite 310, Houston, Texas 77042

Transfer Agent
Empire Stock Transfer

IR/PR Firm
Gregory FCA



FEATURED RELEASE

PetLife Announces Its All-Natural “Cancer Cocktail” with Applicability to Pet and Human Markets

The Company may be the first to offer an all-natural “cancer cocktail” combining the therapeutic benefits of the plant and animal kingdoms.

HANCOCK, MD — June 14, 2017 — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.

PetLife’s new patent-pending formulation has created a “cancer cocktail” combining both Blue Scorpion Venom Chlorotoxin with plant-based phytonutrients. Preliminary testing has shown inhibition against certain cancer cell line studies without toxicity. Across the world, researchers have recognized that many cells which cause disease to have the ability to become resistant to treatment when only one drug is used. Combination therapy is increasing recommended for the treatment of both neoplastic (cancer) and infectious disease. The “HIV Cocktail,” which changed the world approach to the treatment of HIV, is a similar approach comparison. PetLife’s new “cancer cocktail” may prove to be the non-toxic alternative to the harmful and sometimes deadly side effects of radiation and chemotherapy. The patent pending formulation of PetLife’s new “cancer cocktail” has the curious ability to bind selectively to cancer cells and inhibit their growth demonstrating little to no side effects to the patient.

For hundreds, if not thousands of years, plant-based medicinals have formed the foundation of therapeutic treatment in the Chinese, Native American and Ayurvedic traditions. More recently, scientists have discovered the mode of action of many of these therapies. In many cases, the chemical compounds have been manipulated or synthesized to create new chemical entitles (“NCE”). Along with the creation of NCEs comes the inherent risk of unintended consequences and adverse reactions. By maintaining an all-natural formulation, PetLife intends to capture the therapeutic benefit of plant-based therapy without the creation of any unintended consequences. Our team has identified certain phytonutrients which can work synergistically with Blue Scorpion Venom for inhibition of cancer cell growth.

“Our new formulation, RX002CxN, will become the basis of PetLife Pharmaceutical’s new product portfolio, VitalzulTM., a novel treatment option for the treatment of cancer and potentially other indications. The low toxicity of our formulation gives additional benefit. Given the comparative biology of animals and humans, it is our hope that success in treatment of cancer in animals will lead to similar results in humans. Our new formulation has been designed with both human and animal applications in mind. Once testing is completed, the Company will strategically determine the best course of development in both the pet and human markets,” stated Dr. Vivekananda Ramana, Chief Medical Officer of the Company.

“This groundbreaking, patent pending bio technology will serve as the core ingredient in our pharma product Vitalzul™ once we complete the much anticipated FDA trials. It is well known that animal research and studies are the foundation of human applications. Our first goal is to complete the successful testing, FDA application, and commercialization for the benefit of animals. Then, we will move aggressively in expanding our research in the human arena, where we anticipate strong interest from industry leaders,” added Dr. Salvagno.

About PetLife Pharmaceutical
PetLife Pharmaceuticals, Inc. (PTLF) (www.PetLifePharma.com) is a registered U.S. Veterinary Pharmaceutical company. PetLife's mission is to bring its new, non-toxic, bioactive nutraceuticals and prescription medications to the world of veterinary oncology with the ultimate goal of preventing cancer and extending the life of pets suffering from cancer while improving their quality of life. The Company’s first product, Vitalzul™, is currently in testing. Vitalzul™’s active ingredients have been shown to have activity against several different cancer cell lines. In the U.S. alone, consumer spending on domestic companion animals reached over $60 billion in 2015 with over $29 billion spent on veterinary care and medications. PetLife’s acquired brand, Dr. Geoff’s Real Food for Pets, will launch in 2017. PetLife Scorpion Ranch™ will break ground in 2017. PetLife anticipates incorporating Vitalzul™ in a new and advanced therapeutic pet food line in 2019.

Forward looking statement:
This press release contains certain "forward-looking statements," as defined in the United States PSLRA of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The economic, competitive, governmental, technological and other factors identified in the Company's previous filings with the Securities and Exchange Commission may cause actual results or events to differ materially from those described in the forward-looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contact
Clifford Price
clifford@petlifepharma.com
844-473-8543 ext. 701

OTCQB:PTLF Stock Ticker

  • Loading stock data...

Press Release Information

PetLife Pharmaceuticals Gets ‘On the Road Again!’ With 2 Scheduled Road Shows in California
HANCOCK, MD / ACCESSWIRE / July 31, 2017 / PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, is back on the road to bring their message of hope to pet owners in the fight against cancer in our companion animals. While the presentations are targeted to high net worth investors, the Company has found that most of these investors share our passion for our furry friends. They understand our mission to bring an all-natural and cost-effective treatment of cancer through the necessary clinical trials and to make our patent pending product, VitalzulTM, an integral part of cancer treatment.
View Release

PetLife Pharmaceuticals’ CEO, Dr. Ralph Salvagno, Issues Letter to Shareholders

HANCOCK, MD / ACCESSWIRE / July 20, 2017 / PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, has issued a letter to its shareholders from Ralph Salvagno, MD, CEO and Chairman of the Company, as follows:

Dear PetLife Pharmaceuticals Shareholder:

PetLife Pharmaceuticals, Inc. (“PetLife”) continues to make progress towards our goal of bringing effective, affordable and safe products to our companion animals and their pet families.
View Release

PetLife Announces Its All-Natural “Cancer Cocktail” with Applicability to Pet and Human Markets

The Company may be the first to offer an all-natural “cancer cocktail” combining the therapeutic benefits of the plant and animal kingdoms.

HANCOCK, MD — June 14, 2017 — PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, reports on its solution to the ever increasing problem of drug resistance and high toxicity in the treatment of cancer in pets and humans. Each year, in the U.S. alone, more than eleven million cases of cancer in dogs and cats are reported, a number that continues to increase annually.
View Release

PetLife Completes Its TV Commercial for Newly Acquired Dr. Geoff’s by PetLife, Preparing for Regional Launch

Press Release (ePRNews.com) – Hancock, MD – Jun 06, 2017 – PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that its wholly owned subsidiary, Dr. Geoff’s by PetLife, Inc. (“Dr. Geoff’s by PetLife”), PetLife’s product line of natural pet food, supplements, and treats, has initiated its comprehensive product rollout….

View Release

June 1, 2017
PetLife Pharmaceuticals Launches New Website

HANCOCK, MD / May 30, 2017 / PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company,” “PetLife”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced its new Website, www.petlifepharma.com.

View Release

May 30, 2017
PetLife Files for Patent for the Treatment of Cancer for Pets

Combining Chlorotoxin and Plant-based Therapeutics in an Advanced Formulation with New Technology

HANCOCK, MD—May 30, 2017—PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that we have filed for patent protection in India and the United States for the formula for Vitalzul™.
View Release

May 28, 2017
PetLife Management Comments on Recent Market Activity
By AccessWire, May 28, 2017, 02:00:00 AM EDT

HANCOCK, MD / ACCESSWIRE / May 28, 2017 /PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company,” “We”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced the Company’s comments on recent developments in its stock price and trading performance.
View Release

May 26, 2017
PetLife Explores New Scorpion Venom-Based Therapies for Growing Product Line
By AccessWire, May 26, 2017, 06:00:00 AM EDT

HANCOCK, MD / ACCESSWIRE / May 26, 2017 /PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that they are exploring various new products for their product line.
View Release

May 23, 2017
PetLife Closes Acquisition of Assets for Dr. Geoff’s Real Food for Pets
The product line is projected to include VitalZul™ in a second generation of the product in 2018

HANCOCK, MD / ACCESSWIRE / May 23, 2017 / PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that its subsidiary, Dr. Geoff’s by PetLife, Inc. (“Dr. Geoff’s by PetLife”), has completed the acquisition of assets related to the natural pet food product line.
View Release

May 16, 2017
PetLife Pharmaceuticals Engages Carter, Terry & Company for Financing of FDA Application
Press Release (ePRNews.com) – Hancock, Maryland – May 16, 2017 – PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has engaged Carter, Terry & Company (“Carter Terry”), a full-service investment brokerage, investing banking, asset management, and banking services firm, to help finance the development of PetLife’s product development and research to fight cancer in pets and the FDA application. The Company seeks to raise $4 million in this series of financing.
View Release

April 18, 2017
PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets

HANCOCK, Md.–(BUSINESS WIRE)–

PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that it has finalized the negotiations for the acquisition of Dr. Geoff’s Real Food for Pets™. The closing of the acquisition of the trademarked brands and the natural pet food product line is projected to occur within two weeks. VIEW PR

April 12, 2017
PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine

Business Wire

HANCOCK, Md.–(BUSINESS WIRE)–

PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the current state of holistic pet health practices in veterinary medicine. VIEW RELEASE

March 21, 2017
PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets
March 21, 2017 07:00 AM Eastern Daylight Time

HANCOCK, Md.–(BUSINESS WIRE)–PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has proceeded to the next expected stage of acquiring Dr. Geoff’s Real Food for Pets™ and simultaneously has expanded plans for a national rollout.
VIEW PRESS RELEASE

March 7, 2017
PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry – HANCOCK, Md.–(BUSINESS WIRE)–PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the $63 billion companion pet healthcare industry. Empty nesters, reduced fertility, and pet owners prioritizing pet care over their own expenses all contribute to the resiliency of the pet care industry. PetLife’s continuous development of multiple product lines aims to serve the growing companion pet healthcare market, bolstering its market reach and thereby solidifying the company both on a revenue/financial point of view as a natural, solution-focused company.
VIEW PRESS RELEASE

February 28, 2017
PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand – HANCOCK, Md.–(BUSINESS WIRE)–PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it signed a Letter of Intent to acquire the assets of Healthy Life Pets. Most commonly known as Dr. Geoff’s Real Food for Pets™, assets in this brand include six SKUs of retail-ready products, including both canned food and antioxidant supplements.
VIEW PRESS RELEASES

February 20, 2017

PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba- HANCOCK, Md.–(BUSINESS WIRE)–PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
VIEW PRESS RELEASES

February 10, 2017
World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board – Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) — PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the “Company”), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry.
VIEW PRESS RELEASES

January 10, 2017
PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
VIEW PRESS RELEASES

December 7, 2016
PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
VIEW PRESS RELEASES

December 6, 2016
PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission
VIEW PRESS RELEASES

December 1, 2016
PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings
VIEW PRESS RELEASES

November 15, 2016
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom’s Ability to Eradicate Cancer Cells as Continued Support for PetLife’s pre- INAD Studies of Vitalzul™
VIEW PRESS RELEASES

October 27, 2016
PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline
VIEW PRESS RELEASES

October 24, 2016
PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
VIEW PRESS RELEASES

October 19, 2016
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
VIEW PRESS RELEASES

SEC FILINGS

 

EDGAR Information:

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 18, 2017
View Document
View SEC Site

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM NT 10-Q
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): July 18, 2017
View Document
View SEC Site

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 30, 2017
View Document
View SEC Site

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 22, 2017
View Document
View SEC Site

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): April 17, 2017
View Document
View SEC Site

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended February 28, 2017
Commission file number: 000-52445
View Document
View SEC Site

View EDGAR Search Results on SEC.GOV site View Site
PetLife Pharmaceuticals, Inc. CIK#: 0001354591

View all filings page down.

NOTE: IF YOU HAVE PROBLEMS OPENING FILES PLEASE VISIT

SEC.GOV PETLIFE UPDATED INFORMATION – CLICK HERE


—————————-ALL FILING DETAILS AND DOCUMENT LINKS

Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-17-007933 (34 Act)  Size: 2 MB
2017-07-18 000-52445
17969516
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001493152-17-007888 (34 Act)  Size: 26 KB
2017-07-18 000-52445
17968434
8-K  Documents Current report: n, items 1.01 and 9.01

Acc-no: 0001493152-17-006010 (34 Act)  Size: 146 KB

2017-05-31 000-52445
17880436
8-K  Documents Current report: n, items 8.01 and 9.01

Acc-no: 0001493152-17-005975 (34 Act)  Size: 519 KB

2017-05-30 000-52445
17877510
8-K  Documents Current report: n, items 1.01, 5.02, 5.03, and 9.01

Acc-no: 0001493152-17-005865 (34 Act)  Size: 573 KB

2017-05-25 000-52445
17868227
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-17-003868 (34 Act)  Size: 3 MB
2017-04-14 000-52445
17762868
SC 13D  Documents General statement of acquisition of beneficial ownership: n
Acc-no: 0001477932-17-001629 (34 Act)  Size: 612 KB
2017-04-07 005-82533
17750104
4  Documents Statement of changes in beneficial ownership of securities: n
Acc-no: 0001493152-17-002852 Size: 14 KB
2017-03-27
4  Documents Statement of changes in beneficial ownership of securities: n
Acc-no: 0001493152-17-002849 Size: 13 KB
2017-03-24
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001493152-17-002847 Size: 3 KB
2017-03-24
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-17-001329 (34 Act)  Size: 1 MB
2017-02-10 000-52445
17593133
8-K  Documents Current report: n, item 5.02

Acc-no: 0001493152-17-001078 (34 Act)  Size: 26 KB

2017-02-03 000-52445
17570896
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001493152-17-000431 (34 Act)  Size: 31 KB
2017-01-13 000-52445
17526460
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]: v
Acc-no: 0001493152-16-016114 (34 Act)  Size: 2 MB
2016-12-21 000-52445
162064643
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: n
Acc-no: 0001493152-16-015634 (34 Act)  Size: 30 KB
2016-12-05 000-52445
162032602
8-K  Documents Current report: n, item 5.02

Acc-no: 0001493152-16-014213 (34 Act)  Size: 27 KB

2016-10-24 000-52445
161947776
8-K  Documents Current report: n, item 1.01

Acc-no: 0001493152-16-013223 (34 Act)  Size: 22 KB

2016-09-09 000-52445
161878940
8-K  Documents Current report: n, item 1.01

Acc-no: 0001493152-16-013094 (34 Act)  Size: 17 KB

2016-09-02 000-52445
161868796
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-16-011672 (34 Act)  Size: 784 KB
2016-07-21 000-52445
161777259
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001493152-16-011563 (34 Act)  Size: 28 KB
2016-07-15 000-52445
161768982
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001074140-16-000002 Size: 3 KB
2016-06-22
D  Documents Notice of Exempt Offering of Securities: n, item 06c

Acc-no: 0001074140-16-000001 (33 Act)  Size: 6 KB

2016-06-22 021-265521
161725318
DEF 14C  Documents Other definitive information statements: n
Acc-no: 0001493152-16-010126 (34 Act)  Size: 56 KB
2016-05-20 000-52445
161664875
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-16-009048 (34 Act)  Size: 801 KB
2016-04-19 000-52445
161579733
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001493152-16-008956 (34 Act)  Size: 28 KB
2016-04-15 000-52445
161574074
UPLOAD  Documents [Cover]SEC-generated letter: n
Acc-no: 0000000000-16-070262 Size: 36 KB
2016-03-30
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]: n
Acc-no: 0001493152-16-008263 (34 Act)  Size: 62 KB
2016-03-25 000-52445
161528314
8-K  Documents Current report: n, item 5.02

Acc-no: 0001493152-16-008259 (34 Act)  Size: 17 KB

2016-03-25 000-52445
161528227
CORRESP  Documents [Cover]Correspondence: n
Acc-no: 0001493152-16-008261 Size: 89 KB
2016-03-24
UPLOAD  Documents [Cover]SEC-generated letter: n
Acc-no: 0000000000-16-068777 Size: 163 KB
2016-03-17
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-16-006776 (34 Act)  Size: 937 KB
2016-01-14 000-52445
161342454
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]: n
Acc-no: 0001493152-16-006692 (34 Act)  Size: 30 KB
2016-01-08 000-52445
161332575
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]: v
Acc-no: 0001493152-16-006631 (34 Act)  Size: 1 MB
2016-01-06 000-52445
161325304
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]: v
Acc-no: 0001493152-16-006570 (34 Act)  Size: 1 MB
2016-01-05 000-52445
161319989
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-15-006520 (34 Act)  Size: 974 KB
2015-12-31 000-52445
151316233
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-15-006514 (34 Act)  Size: 947 KB
2015-12-31 000-52445
151316196
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001493152-15-006511 (34 Act)  Size: 975 KB
2015-12-31 000-52445
151316170
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]: v
Acc-no: 0001493152-15-006481 (34 Act)  Size: 1 MB
2015-12-31 000-52445
151315440
8-K  Documents Current report: n, items 4.01 and 9.01

Acc-no: 0001493152-15-006412 (34 Act)  Size: 36 KB

2015-12-28 000-52445
151307906
NTN 10K  Documents Notices of Late Filings of Form 10-K or 10-KSB: n
Acc-no: 0001493152-15-005993 (34 Act)  Size: 30 KB
2015-12-02 000-52445
151263457
Filings Format Description Filing Date File/Film Number
SC 13D  Documents General statement of acquisition of beneficial ownership: n
Acc-no: 0001360865-15-000011 (34 Act)  Size: 30 KB
2015-05-15 005-82533
15871144
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001360865-15-000001 (34 Act)  Size: 12 KB
2015-01-15 000-52445
15529432
10-K  Documents Annual report [Section 13 and 15(d), not S-K Item 405]: n
Acc-no: 0001360865-14-000061 (34 Act)  Size: 442 KB
2014-12-16 000-52445
141288078
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: n
Acc-no: 0001360865-14-000059 (34 Act)  Size: 12 KB
2014-12-01 000-52445
141257550
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001360865-14-000053 Size: 3 KB
2014-10-03
8-K  Documents Current report: n, item 5.02

Acc-no: 0001360865-14-000052 (34 Act)  Size: 10 KB

2014-10-03 000-52445
141138909
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001360865-14-000051 Size: 3 KB
2014-09-29
SC 13D  Documents General statement of acquisition of beneficial ownership: n
Acc-no: 0001360865-14-000050 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125941
SC 13D  Documents General statement of acquisition of beneficial ownership: n
Acc-no: 0001360865-14-000049 (34 Act)  Size: 25 KB
2014-09-29 005-82533
141125929
SC 13D  Documents General statement of acquisition of beneficial ownership: n
Acc-no: 0001360865-14-000048 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125913
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001360865-14-000046 Size: 3 KB
2014-09-23
3  Documents Initial statement of beneficial ownership of securities: n
Acc-no: 0001360865-14-000045 Size: 3 KB
2014-09-23
8-K  Documents Current report: n, items 1.01, 2.01, 3.02, 5.01, 5.02, and 9.01

Acc-no: 0001360865-14-000037 (34 Act)  Size: 455 KB

2014-08-11 000-52445
141031256
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001079974-14-000573 (34 Act)  Size: 2 MB
2014-08-05 000-52445
141015287
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001079974-14-000572 (34 Act)  Size: 2 MB
2014-08-05 000-52445
141015272
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001079974-14-000571 (34 Act)  Size: 2 MB
2014-08-05 000-52445
141015249
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]: v
Acc-no: 0001079974-14-000556 (34 Act)  Size: 3 MB
2014-07-21 000-52445
14985197
NTN 10Q  Documents Notices of Late Filings of Form 10-Q or 10-QSB: n
Acc-no: 0001079974-14-000554 (34 Act)  Size: 25 KB
2014-07-17 000-52445
14980439
8-K  Documents Current report: n, items 1.01 and 9.01

Acc-no: 0001079974-14-000318 (34 Act)  Size: 334 KB

2014-04-29 000-52445
14792847
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: n
Acc-no: 0001079974-13-000770 (34 Act)  Size: 24 KB
2013-12-02 000-52445
131252475
10-Q/A  Documents [Amend] Quarterly report [Sections 13 or 15(d)]: n
Acc-no: 0001079974-13-000547 (34 Act)  Size: 682 KB
2013-08-23 000-52445
131058316
8-K  Documents Current report: n, item 4.02

Acc-no: 0001079974-13-000425 (34 Act)  Size: 27 KB

2013-07-30 000-52445
13994423
10-Q  Documents Quarterly report [Sections 13 or 15(d)]: n
Acc-no: 0001079974-13-000412 (34 Act)  Size: 696 KB
2013-07-23 000-52445
13981892
8-K  Documents Current report: n, items 3.03, 5.03, and 9.01

Acc-no: 0001079974-13-000402 (34 Act)  Size: 622 KB

2013-07-19 000-52445
13977367
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001360865-13-000125 (34 Act)  Size: 11 KB
2013-07-16 000-52445
13970976
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001079974-13-000399 (34 Act)  Size: 24 KB
2013-07-16 000-52445
13970699
10-Q  Documents Quarterly report [Sections 13 or 15(d)]: n
Acc-no: 0001079974-13-000207 (34 Act)  Size: 728 KB
2013-04-23 000-52445
13777286
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001079974-13-000194 (34 Act)  Size: 24 KB
2013-04-15 000-52445
13761513
10-Q  Documents Quarterly report [Sections 13 or 15(d)]: n
Acc-no: 0001360865-13-000002 (34 Act)  Size: 355 KB
2013-01-18 000-52445
13537981
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001360865-13-000001 (34 Act)  Size: 11 KB
2013-01-14 000-52445
13528558
10-K  Documents Annual report [Section 13 and 15(d), not S-K Item 405]: n
Acc-no: 0001360865-12-000304 (34 Act)  Size: 660 KB
2012-12-27 000-52445
121285932
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: n
Acc-no: 0001360865-12-000301 (34 Act)  Size: 11 KB
2012-11-29 000-52445
121232587
DEF 14C  Documents Other definitive information statements: n
Acc-no: 0001360865-12-000197 (34 Act)  Size: 43 KB
2012-09-18 000-52445
121096594
8-K  Documents Current report: n, items 5.02, 7.01, and 8.01

Acc-no: 0001096906-12-002405 (34 Act)  Size: 16 MB

2012-09-13 000-52445
121089643
8-K  Documents Current report: n, items 1.01 and 9.01

Acc-no: 0001096906-12-001894 (34 Act)  Size: 612 KB

2012-08-07 000-52445
121014019
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]: v
Acc-no: 0001096906-12-001843 (34 Act)  Size: 1 MB
2012-07-23 000-52445
12974385
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB: n
Acc-no: 0001096906-12-001812 (34 Act)  Size: 34 KB
2012-07-16 000-52445
12963520
UPLOAD  Documents [Cover]SEC-generated letter: n
Acc-no: 0000000000-12-034875 Size: 36 KB
2012-07-03
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]: n
Acc-no: 0001096906-12-001695 (34 Act)  Size: 1 MB
2012-06-19 000-52445
12915815
PRE 14C  Documents Other preliminary information statements: n
Acc-no: 0001360865-12-000099 (34 Act)  Size: 43 KB
2012-06-12 000-52445
12901477

View EDGAR Search Results on SEC.GOV site View Site
PetLife Pharmaceuticals, Inc. CIK#: 0001354591